Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer. Baraban E, Erak E, Fatima A, Akbari A, et al. J Urol 2023 Apr 12:101097JU0000000000003461. doi: 10.1097/JU.0000000000003461.

Read + Share

Amedeo Smart

Independent Medical Education

Baraban E, Erak E, Fatima A, Akbari A, et al. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer. J Urol 2023 Apr 12:101097JU0000000000003461. doi: 10.1097/JU.0000000000003461.
PMID: 37042826